Last checked at 22 Jun 2016 12:00
Faron Pharmaceuticals Ltd
("Faron" or the "Company")
Faron to Present at the Proactive Investors One2One Forum on 22 June 2016
TURKU - FINLAND 22 June 2016 - Faron Pharmaceuticals Ltd (LON: FARN), the clinical stage biopharmaceutical company, announces today that Markku Jalkanen, Chief Executive Officer, is scheduled to present at the Proactive Investors One2One Forum on Wednesday 22 June 2016 at 6:00pm in London.
The event will be held at Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB from 6:00pm to 8:00pm, followed by a drinks reception.
This event is open to private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.
Further information can found at: http://www.proactiveinvestors.co.uk/register/event_details/63
For more information, please contact:
Faron Pharmaceuticals Oy
Katja Wallenlind
Phone +358 (50) 577 4807E-mail: katja.wallenlind@faronpharmaceuticals.com
Hume Brophy, PR
Mary Clark, Eva Haas, Hollie Vile
Phone: +44 207 862 6390
E-mail: faron@humebrophy.com
Cairn Financial Advisers LLP, Nominated Adviser
Emma Earl, Tony Rawlinson and Rebecca Anderson
Phone: +44 207 148 7900
Panmure Gordon (UK) Limited, Joint Broker
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Phone: +44 207 886 2500
Whitman Howard Limited, Nominated Broker
Ranald McGregor-Smith, Francis North
Phone: +44 207 659 1234
About Faron Pharmaceuticals Ltd
Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat Acute Respiratory Distress Syndrome ("ARDS"), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen®. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach called TIET (Tumour Immunity Enabling Technology). Faron Pharmaceuticals Ltd is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com